CORRECTED-BRIEF-Merck Says Vericiguat Significantly Reduced Risk Of Composite Endpoint Of HF Hospitalization Or Cardiovascular Death, Vs Placebo

* INVESTIGATIONAL DRUG VERICIGUAT SIGNIFICANTLY REDUCED THE RISK OF THE COMPOSITE ENDPOINT OF HEART FAILURE HOSPITALIZATION OR CARDIOVASCULAR DEATH, COMPARED TO PLACEBO, WHEN GIVEN IN COMBINATION WITH AVAILABLE HEART FAILURE THERAPIES